Heart drug 'safe for kidney patients'
Blood cells: ‘bad’ cholesterol puts the hearts of kidney patients at risk.
(Medical Xpress) -- The full results of a trial show that people with chronic kidney disease can reduce their heart risk by taking a combination drug that lowers levels of bad cholesterol.
Taking cholesterol-lowering drugs such as statins to combat heart disease is pretty standard in people without kidney problems.
But there was a great deal of uncertainty about using such treatments in people with impaired kidney function because of concerns about drug toxicity (the kidneys are key in getting rid of harmful substances). This is despite kidney patients being at high risk of heart problems.
The study findings were first reported at an American Society of Nephrology conference in Denver in November, but the full results have now been published in The Lancet.
The SHARP trial found that patients receiving the daily pill a combination of simvastatin and ezetimibe produced by Merck had one-sixth fewer heart attacks, strokes or operations to unblock arteries than those receiving a placebo dummy pill. And importantly, there were no safety concerns with the drug, which is already being taken by many people with normal kidney function to lower their cholesterol.
Professor Colin Baigent of the Clinical Trial Service Unit (CTSU) at Oxford University, the trials principal investigator, says: This is good news for kidney patients. People with this disease are in desperate need of new treatments not only to combat the disease itself, but also to reduce pain and suffering, such as heart attacks and strokes, due to side effects of the illness.
Over half of people with kidney disease will eventually be killed, not by their kidney disease, but by cardiovascular diseases. We now know there is something we can do about this and I believe this study will have a positive impact on the lives of many millions of people currently being treated for chronic kidney disease in the UK and around the world.
Chronic kidney disease is very common, affecting up to one in twenty of the middle-aged population, and substantially more of those who are older. Although people with chronic kidney disease are known to have an increased risk of a stroke or heart attack, it has been very unclear what treatments could prevent these conditions in this group of patients.
Dr Martin Landray, co-principal investigator of the trial at CTSU, says: Some doctors had thought that damaged kidneys might cause a type of cardiovascular disease that would not be preventable by lowering cholesterol, but the SHARP trial showed clearly that lowering cholesterol does reduce the risk of cardiovascular disease in people with kidney disease.
The culmination of this long-running, large-scale trial involving 9,500 patients in 18 countries planning for which began in the 1990s marks the end of work in which Colin Baigent has had a great personal interest.
He developed kidney disease himself 30 years ago and needed dialysis before receiving a kidney transplant. He is clear that, Many of the young people who were receiving dialysis at the same time as me are now dead from cardiovascular disease.
Progress in the prevention of cardiovascular disease with drug treatments in kidney patients has lagged behind other patient groups, he says. The research community has tended to neglect testing promising treatments in kidney patients, partly because of fears that some drugs may turn out to be dangerous in people with damaged kidneys.
The SHARP study now shows clearly, however, that it is possible to find safe and effective drugs for the prevention of cardiovascular disease in kidney patients.
With over 3% of the NHS budget currently devoted to treating kidney patients, and that figure likely to rise, there is a need for better care of such patients, and the prevention of cardiovascular disease should be a high priority, says Colin Baigent.
More information: www.thelancet.com/… 9-3/fulltext
Provided by Oxford University
- Cholesterol drug shows benefits for kidney patients Nov 22, 2010 | not rated yet | 0
- 'Statins' linked to improved survival in kidney transplant recipients Jul 24, 2008 | not rated yet | 0
- Poor kidney function linked to future heart and brain problems Sep 30, 2010 | not rated yet | 0
- Kidney disease linked to lower medication use after heart attack Jul 09, 2008 | not rated yet | 0
- Low thyroid function common in chronic kidney disease Jun 11, 2008 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013 Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...
Medications 8 hours ago | not rated yet | 0
(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.
Medications May 23, 2013 | 1 / 5 (1) | 0
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
Medications May 23, 2013 | 5 / 5 (1) | 0
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications May 22, 2013 | not rated yet | 0
(HealthDay)—Animals make great companions for senior citizens, but elderly people who always drive with a pet in the car are far more likely to crash than those who never drive with a pet, researchers have ...
14 minutes ago | not rated yet | 0
Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...
8 hours ago | 5 / 5 (2) | 5
Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...
8 hours ago | not rated yet | 1
Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...
8 hours ago | not rated yet | 0
Talking on a hands-free device while behind the wheel can lead to a sharp increase in errors that could imperil other drivers on the road, according to new research from the University of Alberta.
23 hours ago | not rated yet | 1